Keywords: Astellas, Qutenza, EU application, New Indication, Neuropathic pain

Astellas pulls EU application to extend use of Qutenza

Article | 20 March 2012

Print This

The European Medicines Agency has been formally notified by Astellas Pharma Europe, a subsidiary of Japanese drug major Astellas (TYO: 4503) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in